

REVIEW

cAMP and Epac in the regulation of tissue fibrosis

Paul A Insel^{1,2*}, Fiona Murray^{1,2*}, Utako Yokoyama^{1,3}, Silvia Romano^{1,4}, Hongruo Yun¹, Loren Brown¹, Aaron Snead¹, David Lu¹ and Nakon Aroonsakool^{1,2}

Departments of ¹Pharmacology and ²Medicine, University of California San Diego, La Jolla, California, USA, ³Cardiovascular Research Institute, City University of Yokohama, Yokohama, Japan, and ⁴Department of Biomedical Sciences, 'G. D'Annunzio' University of Chieti-Pescara, Italy

Correspondence

Paul A Insel, Mail code 0636, Dept. of Pharmacology, UCSD, La Jolla, CA 92093, USA. E-mail: pinsel@ucsd.edu

*Co-first authors.

Keywords

cyclic AMP; Epac; fibrosis; G protein-coupled receptors; protein kinase A; MDCK cell; myofibroblast; protein kinase A; TGF- β

Received

23 September 2011

Revised

16 November 2011

Accepted

11 December 2011

Fibrosis, the result of excess deposition of extracellular matrix (ECM), in particular collagen, leads to scarring and loss of function in tissues that include the heart, lung, kidney and liver. The second messenger cAMP can inhibit the formation and extent of ECM during this late phase of inflammation, but the mechanisms for these actions of cAMP and of agents that elevate tissue cAMP levels are not well understood. In this article, we review the fibrotic process and focus on two recently recognized aspects of actions of cAMP and its effector Epac (Exchange protein activated by cAMP): (a) blunting of epithelial-mesenchymal transformation (EMT) and (b) down-regulation of Epac expression by profibrotic agents (e.g. TGF- β , angiotensin II), which may promote tissue fibrosis by decreasing Epac-mediated antifibrotic actions. Pharmacological approaches that raise cAMP or blunt the decrease in Epac expression by profibrotic agents may thus be strategies to block or perhaps reverse tissue fibrosis.

LINKED ARTICLES

This article is part of a themed section on Novel cAMP Signalling Paradigms. To view the other articles in this section visit <http://dx.doi.org/10.1111/bph.2012.166.issue-2>

Abbreviations

CF, cardiac fibroblast; ECM, extracellular matrix; Epac, Exchange protein activated by cyclic AMP; 8-Me-cAMP, 8-CPT-2'-O-Me-cAMP; N6-cAMP, N6-Benzoyl-cAMP; NSAIDs, non-steroidal anti-inflammatory drugs; α -SMA, α -smooth muscle actin

Introduction to tissue fibrosis and cAMP signalling

Tissue fibrosis

Tissue fibrosis (scarring) results from the excess deposition of extracellular matrix (ECM) and occurs as part of normal physiology (e.g. aging) and following injury, in particular, with recurrent or persistent stimulation of the inflammatory process. Tissue fibrosis often alters tissue function. For example, cardiac fibrosis contributes to diastolic dysfunction and a decrease in cardiac output that accompany advanced age (Lakatta, 2003; Chen and Frangogiannis, 2010). Inflammation that follows tissue injury produces a series of acute and late-phase responses. In its acute phase, inflammation is characterized by several cardinal features [calor, rubor, dolor

and tumour (heat, redness, pain and swelling)], which can be treated by pharmacological agents, in particular non-steroidal anti-inflammatory drugs (NSAIDs), whose major action is inhibition of COXs and thus the synthesis of prostaglandins.

Much less is known regarding the mechanisms that mediate the late phase of inflammation during which resolution of the tissue infiltration of acute inflammatory cells occurs, but tissue fibrosis can be initiated. Recent efforts have helped identify mechanisms of the resolution of inflammation (Serhan, 2010; Maskrey *et al.*, 2011; Wynn, 2011; Yates *et al.*, 2011). Glucocorticoids, the principal class of drugs used to treat this phase of the inflammatory process, block protein synthesis, thereby decreasing the accumulation of collagens and other ECM proteins. However, the use of glucocorticoids is associated with numerous side effects. Pirfenidone is a

1. Differentiation and/or activation of tissue resident cells




Figure 1

Heterogeneous origin of myofibroblasts. Myofibroblasts, which synthesize and secrete ECM, including collagens I and III, and contribute to fibrosis, originate from various sources, which include the following:

- (1) Differentiation of fibroblasts, activation of pericytes (e.g. hepatic stellate cells) and de-differentiation of muscle cells;
- (2) EMT or endothelial–mesenchymal transformation (transition);
- (3) Recruitment of circulating fibrocytes derived from the bone marrow.

recently available antifibrotic agent whose mechanism of action is, at least in part, inhibition of the production and activity of TGF- β , a cytokine with strong profibrotic actions (Cho and Kopp, 2010). The wide prevalence of diseases associated with tissue fibrosis and the increasing age of the population (which is accompanied by such disorders) provide a strong impetus for the discovery of new antifibrotic agents.

A key goal in developing treatments for fibrosis is the avoidance of tissue damage and resolution of the remodelling that occur as a consequence of deposition of ECM with a resultant decrease in tissue parenchyma and function. Although certain types of tissue fibrosis can be reversed, it is generally irreversible, especially if its extent produces substantial loss of tissue parenchyma (Wallace *et al.*, 2007; Marian, 2009; Ramachandran and Iredale, 2009; Chen and Frangogiannis, 2010; Dussault *et al.*, 2011). The main cell responsible for tissue remodelling during fibrosis is the myofibroblast. Myofibroblasts, α -smooth muscle actin–expressing cells that secrete ECM components and collagen type I and III, originate from a number of sources that depend on the physiological stimulus and the tissue in which the insult occurs. The mechanisms that contribute to the increase in the number of myofibroblasts in fibrosis are outlined in Figure 1 and include (Krenning *et al.*, 2010; Pinzani and Macias-Barragan, 2010; Meran and Steadman, 2011) (1) mitosis of tissue-resident fibroblasts and their phenotypic ‘switch’ to profibrotic myofibroblasts (Hinz, 2010); (2) altered stem cell differentiation or de-differentiation of other cell types into fibroblasts (Brack *et al.*, 2007); (3) activation and migration of stromal cells, pericytes, particularly in kidney fibrosis (Armulik *et al.*, 2011; Schrimpf and Duffield, 2011); (4) con-

version of epithelial or endothelial cells to fibroblasts, via epithelial–mesenchymal transformation (termed EMT) or endothelial–mesenchymal transformation, respectively; and (5) entry of bone marrow-derived, circulating fibrocytes into inflammatory sites (Grieb *et al.*, 2011). The relative contribution of these various mechanisms to fibrosis is a topic of considerable current debate along with the question as to whether myofibroblasts derived in different ways and from different tissues exhibit different characteristics and functions; since myofibroblasts produce mediators that contribute to the fibrotic process, attenuation of their recruitment and activation are approaches to treat tissue fibrosis (Hinz, 2010; Humphreys *et al.*, 2010; Krenning *et al.*, 2010; Pinzani and Macias-Barragan, 2010; Kriz *et al.*, 2011; Meran and Steadman, 2011).

cAMP signalling

The second messenger cAMP is as a regulator of fibroblast function. cAMP is generated by ACs in response to activation of GPCRs and degraded by cyclic nucleotide PDEs. cAMP acts via three mechanisms to modulate tissue responses: PKA, Epac and cyclic nucleotide-gated (CNG) ion channels. The cAMP effector, Epac (Exchange protein activated by cAMP) (Gloerich and Bos, 2010; Grandoch *et al.*, 2010; Breckler *et al.*, 2011), has recently been identified as an important mediator of the antifibrotic effect of cAMP and will be discussed in more detail below. As reviewed in the references cited above, the two forms of Epac, Epac1 and Epac2, respectively possess one and two cAMP binding sites and function as guanine nucleotide exchange factors for the low molecular weight G-protein Rap (e.g. Rap1 and Rap2). Epac proteins regulate numerous cellular responses through their ability to promote the exchange of GTP for GDP on Raps and perhaps other G-proteins (Gloerich and Bos, 2010; Grandoch *et al.*, 2010; Breckler *et al.*, 2011). cAMP analogues that selectively activate PKA or Epac (Bos, 2006; Holz *et al.*, 2008) can aid in defining their role as effectors of cellular responses.

Increases in cAMP levels inhibit fibroblast function and produce antifibrotic effects that include (Table 1) decrease in fibroblast proliferation, stimulation of the death of fibroblasts and inhibition of ECM protein synthesis. Such effects can occur in response to increases in cAMP by agonists/antagonists of GPCRs, activation of ACs, inhibition of PDEs or use of cAMP analogues. The precise mechanisms for the antifibrotic effects of cAMP that are summarized in Table 1 are not clearly defined. We will discuss two aspects of cAMP/Epac-regulated actions that influence tissue fibrosis: (1) inhibition by cAMP of EMT and an associated decrease in synthesis of ECM components by fibroblasts and (2) inhibition by profibrotic agents of Epac expression, thereby blunting its antifibrotic actions. In addition, we discuss the roles of cAMP effectors in fibrosis and provide some therapeutic implications of these actions.

Myofibroblast transformation is inhibited by cAMP via Epac and PKA

EMT

EMT has been proposed as a mechanism for tissue fibrosis in numerous settings, including in development, cancer and

Table 1

Antifibrotic actions of cAMP

Action	References	Cell type
Inhibition of formation and action of profibrotic growth factors/hormones	Windmeier and Gressner, 1997 Kothapalli <i>et al.</i> , 1998 Heusinger-Ribeiro <i>et al.</i> , 2001 Yu <i>et al.</i> , 2002 Swaney <i>et al.</i> , 2005 Liu <i>et al.</i> , 2006 Black <i>et al.</i> , 2007 Clancy <i>et al.</i> , 2007	Rat hepatic fibroblasts Rat kidney interstitial fibroblasts (NRK-49F) Immortalized human renal fibroblasts Rat-1 Fibroblasts Rat cardiac fibroblasts Rat cardiac fibroblasts Human gingival fibroblasts Human Fetal Cardiac Fibroblasts
Decrease in fibroblast proliferation and fibroblast → myofibroblast conversion	Dunkern <i>et al.</i> , 2007 Huang <i>et al.</i> , 2008 Xing and Bonanno, 2009 Sandbo <i>et al.</i> , 2009 Selige <i>et al.</i> , 2010 Liu <i>et al.</i> , 2004; 2005; 2010 Stumm <i>et al.</i> , 2011	Human lung fibroblasts, fibroblast cell line IMR-90, fetal human fibroblast cell line GM06114 Human fetal lung fibroblast cell line IMR-90, primary human lung fibroblasts Primary rabbit corneal keratocytes Human pulmonary fibroblasts Human lung fibroblasts Rat pulmonary fibroblasts, murine pulmonary fibroblasts Murine lung fibroblasts
Promotion of cell death of fibroblasts	Huang <i>et al.</i> , 2009 Insel <i>et al.</i> , 2012b Zhang <i>et al.</i> , 2011	Human fetal lung fibroblast cell line IMR-90, primary human lung fibroblasts Various Rat cardiac fibroblasts
Decrease in fibroblast motility	Sandulache <i>et al.</i> , 2006; 2007 Yokoyama <i>et al.</i> , 2008 Togo <i>et al.</i> , 2009 Kohyama <i>et al.</i> , 2009	Human fetal dermal fibroblast, human adult dermal fibroblast Rat cardiac fibroblasts Human fetal lung fibroblasts (HFL-1) Human fetal lung fibroblasts (HFL-1)
Decrease in synthesis/release/function of ECM components	Parekh <i>et al.</i> , 2007 Sachs <i>et al.</i> , 2007 Liu <i>et al.</i> , 2008 Parekh <i>et al.</i> , 2009 Huang <i>et al.</i> , 2008 Liu <i>et al.</i> , 2004; 2005; 2010 Bauman <i>et al.</i> , 2010 Chan <i>et al.</i> , 2010 D'Souza <i>et al.</i> , 2011 Okunishi <i>et al.</i> , 2011 Miller <i>et al.</i> , 2011	Human fetal dermal fibroblast, human adult dermal fibroblast Murine lung fibroblasts Rat cardiac fibroblasts Human fetal dermal fibroblast, human adult dermal fibroblast Human fetal lung fibroblast cell line IMR-90, primary human lung fibroblasts Rat pulmonary fibroblasts, murine pulmonary fibroblasts Murine lung fibroblasts, human fetal lung fibroblast cell line IMR-90 Murine cardiac fibroblasts Human cardiac fibroblasts Murine lung fibroblasts Murine and rat fibroblasts

diseases of many organs (Hinz, 2010; Humphreys *et al.*, 2010; Krenning *et al.*, 2010; Chaffer and Weinberg, 2011; Kriz *et al.*, 2011; Meran and Steadman, 2011). A commonly used model to study EMT is to ligate one of the ureters and observe the resultant changes in the kidney. Other studies of EMT have used renal epithelial cells, such as the distal tubule/collecting duct-derived MDCK cells. MDCK cells treated with TGF- β show changes that occur with EMT (Zhang *et al.*, 2006a,b; Park *et al.*, 2007; Cufi *et al.*, 2010; Li *et al.*, 2010; Figure 2): loss

of expression of E-cadherin (and other proteins characteristic of epithelial cells) and increased expression of α -smooth muscle actin (α -SMA) [and also vimentin, fibronectin and collagens (proteins characteristic of fibroblasts; data not shown)]. We observe such changes in parental MDCK cells treated with TGF- β but not in MDCK-D1 cells, a clonal isolate that has enriched expression of α_{1b} - and β_2 -adrenoceptors (Klijn *et al.*, 1991; data not shown). Parental MDCK cells represent a mixture of renal cell types; an extensive literature




Figure 2

Markers of EMT. EMT involves a transition of polarized epithelial cells, which normally interact with the basement membrane, into migratory spindle-like, ECM-producing mesenchymal cells. The figure lists some commonly used markers that distinguish the two phenotypes.

documents that clonal isolates can have properties that differ from those present in the parental cells (e.g. Meier *et al.*, 1983).

Increases in cAMP by agents that activate AC, PDE inhibitors or cAMP analogues inhibits EMT in MDCK cells (Zhang *et al.*, 2006a,b; Figures 3 and 4). Based on their epithelial phenotype, parental MDCK cells have high expression of E-cadherin but express little or no α -SMA: TGF- β induces transition to a mesenchymal phenotype by increasing α -SMA and decreasing E-cadherin expression (Figures 3 and 4). Treatment of these MDCK cells with a cAMP derivative that selectively activates Epac (8-Me-cAMP, 50 μ M) but not with a PKA-selective cAMP agonist (N6-cAMP, 50 μ M) blunts the increase in α -SMA (Figures 3 and 4). By contrast, both 8-Me-cAMP and N6-cAMP attenuate the TGF- β -promoted inhibition of E-cadherin expression. Thus, inhibition of aspects of EMT by cAMP in MDCK cells involves both Epac and PKA.

Fibroblast-myofibroblast transformation

Studies with adult rat cardiac fibroblasts (CF) reveal that increasing cAMP formation by the overexpression of AC6 or by activating AC with forskolin blunts collagen synthesis, TGF- β - or angiotensin II-stimulated increase in α -SMA expression, actin/focal adhesion assembly and, in parallel, the transformation of fibroblasts to myofibroblasts (Swaney *et al.*, 2005). Experiments conducted with N6-cAMP and 8-Me-cAMP indicate that activation of either PKA or Epac inhibit expression of collagens I and III; by contrast, Epac and PKA have opposing effects on CF migration (Yokoyama *et al.*, 2008). Such data are consistent with results observed with other fibroblasts, such as those from the lung (Huang *et al.*, 2008).

Regulation of Epac expression by profibrotic agents

Our studies with MDCK cells (Figure 5) and primary cultures of rat cardiac fibroblasts (Yokoyama *et al.*, 2008) reveal that treatment with profibrotic agents decreases the expression of Epac, results confirmed by others (Basoni *et al.*, 2005). Prevention of this decrease in Epac expression inhibits profibrotic response (Yokoyama *et al.*, 2008), thus implying the importance of the decrease in Epac for this response.

Treatment of MDCK cells with profibrotic agents decreases expression of Epac2, which is expressed at much higher levels than Epac1 in these cells (Figure 5), but in fibroblasts from multiple tissues, profibrotic agents only decrease expression of Epac1 (Yokoyama *et al.*, 2008). Thus, profibrotic agents can down-regulate expression of both isoforms of Epac and Epac-mediated signalling, such as activation of Rap-1, but alter expression of different isoforms in different tissues.

The roles of cAMP and Epac in tissue fibrosis and therapeutic implications

The information provided above implies that therapeutic approaches that increase cAMP or that activate Epac or increase its expression have the potential to decrease tissue fibrosis (Figure 6). Although PKA was initially thought to be the exclusive mediator of cAMP action (Insel *et al.*, 1975), Epac mediates numerous effects of cAMP (Gloerich and Bos,




Figure 3

Activation of Epac, but not PKA, attenuates the TGF- β -induced increase in α -SMA in MDCK cells. Immunocytochemistry demonstrates that Epac activation (8Me-cAMP, 50 μ M, 72 h), but not PKA activation (N6-cAMP, 50 μ M, 72 h) inhibits the increase in α -SMA (stained red) induced by TGF- β 1 (5 ng·mL⁻¹, 72 h), 40 $\times$ objective. Data are representative of three separate experiments. Bar equals 10 μ m.




Figure 4

Activation of either Epac or PKA reverses characteristics of EMT in MDCK cells. Representative immunoblot reveals that MDCK cells treated with TGF- β 1 (5 ng·mL⁻¹, 72 h) show changes associated with EMT (increased α -SMA and loss of E-cadherin). Epac activation (8Me-cAMP, 50 μ M, 72 h) inhibits the increase in α -SMA and the decrease in E-cadherin, whereas PKA activation (N6-cAMP, 50 μ M, 72 h) only prevents the decrease in E-cadherin. Lower panel, immunoblots were quantified and normalized to GAPDH expression. $n = 3$; * $P < 0.05$ versus control; # $P < 0.05$, versus TGF- β .




Figure 5

Epac2 expression is markedly decreased in MDCK cells by TGF- β . Upper left panel, Epac-1 and Epac2 mRNA expression in MDCK cells (by real-time PCR, results normalized to GAPDH) shows that Epac2 is expressed at higher levels than is Epac1 $n = 3$; ** $P < 0.001$ compared with Epac1. Lower left panel, treatment with 5 ng·mL⁻¹ TGF β 1 for 72 h decreases Epac2 mRNA expression (by real-time PCR) $n = 3$; * $P < 0.05$ versus vehicle. The data are expressed as fold change relative to vehicle-treated MDCKs. Upper right panel, a representative immunoblot shows that Epac2 protein expression is decreased in MDCK cells treated with 5 ng·mL⁻¹ TGF- β 1 for 72 h. Lower right panel, immunoblots were quantified and normalized to GAPDH expression. $n = 3$; * $P < 0.05$, versus vehicle.




Figure 6

Model of the antifibrotic effects of cAMP. After injury, profibrotic stimuli (e.g. Ang II and TGF- β 1) activate fibroblasts, increase ECM synthesis and deposition (e.g. collagens I and III), and regulate expression of fibrotic genes (e.g. α -SMA). Pharmacological agents that increase intracellular cAMP (Gs-linked GPCR agonists, Gi-linked GPCR antagonists, AC activators, or PDE inhibitors) can inhibit the profibrotic effects of Ang II and TGF- β 1, potentially through SMAD inhibition. cAMP activation of Epac1 and PKA lowers expression of collagens I and III but has opposite effects on cell migration.

2010; Grandoch *et al.*, 2010; Breckler *et al.*, 2011). One such effect is the inhibition of EMT, although both PKA and Epac regulate features characteristic of EMT in MDCK cells (Figures 3 and 4). The contribution of EMT to tissue fibrosis *in vivo* is controversial (Hinz, 2010; Humphreys *et al.*, 2010; Kriz *et al.*, 2011; Quaggin and Kapus, 2011). Even so, the activation of Epac, potentially either Epac1 or Epac2 in different tissues, can regulate profibrotic responses, including collagen and DNA synthesis and other functional activities of fibroblasts. Data in rat cardiac, lung and skin fibroblasts show Epac1 is preferentially decreased in response to profibrogenic agonists; however, Epac2 is decreased by the same stimuli in MDCK cells (Figure 5; Yokoyama *et al.*, 2008). Other data implicate increases in cAMP as a means to inhibit EMT (Zhang *et al.*, 2006a,b; Kim *et al.*, 2009; Kolosionek *et al.*, 2009) and of PKA-mediated phosphorylation to influence proteins that regulate EMT (MacPherson *et al.*, 2010).

Recent information emphasizes the contribution of various transcription factors (e.g. Snail, Slug, Twist, etc.) to EMT and mechanisms that regulate their expression. EMT is thought to play an important role in pathophysiology in cancer and cancer cell metastases, with EMT-associated features representing signals expressed after the formation of primary tumours (Chaffer and Weinberg, 2011). The contribution of EMT to tissue fibrosis is controversial in a number of other settings, in part because not all features of the 'EMT phenotype' are consistently observed, especially between *in*

vitro and *in vivo* models. A 'two-hit' model has been proposed that involves (1) disruption of intercellular contact between epithelial cells and (2) promotion of fibrotic features by TGF- β (Masszi *et al.*, 2010). A consequence of the disruption of intercellular contact is the nuclear translocation of myocardium-related transcription factor (MRTF), which binds to a region in the α -SMA gene promoter. This promoter region contains TGF- β -responsive Smad3-binding elements. Smad3 has been proposed to be a critical timer/delayer of development of EMT and to differentially affect various components of EMT (Masszi *et al.*, 2010; Masszi and Kapus, 2011). It will thus be of interest to determine the impact of cAMP, Epac and PKA on these recently recognized regulators of EMT. Of note, Smad3 and the regulatory subunits of PKA have been shown to coimmunoprecipitate and cAMP via PKA inhibits SMAD-mediated transcription (Schiller *et al.*, 2003; Yang *et al.*, 2008).

The ability of profibrotic stimuli to inhibit expression of Epac likely contributes to cardiac fibrosis because overexpression of Epac blocks profibrotic response and Epac expression decreases at sites that have fibrotic activity (Figure 5; Yokoyama *et al.*, 2008). The mechanisms that regulate Epac expression and inhibition of its expression by profibrotic stimuli remain to be determined; little is known regarding the transcriptional and post-transcriptional regulation of Epac expression (Basoni *et al.*, 2005; Brown *et al.*, 2011). Epac also has other roles, including altering cell migration, that may relate to its actions in fibrosis (Yokoyama *et al.*, 2008;

Grandoch *et al.*, 2010; Breckler *et al.*, 2011; Mironov *et al.*, 2011; Stokman *et al.*, 2011). siRNA-mediated inhibition of Epac1 (but not Epac2) in rat cardiac fibroblasts and its downstream mediator Rap-1 decreases cAMP-induced migration of cardiac fibroblasts, implying a role for Epac1 signalling via Rap-1 in the antifibrotic actions of cAMP (Yokoyama *et al.*, 2008). In contrast, Rap1-targeted siRNA did not affect Epac-induced inhibition of collagen and DNA synthesis, thus suggesting a role for other downstream mediators of Epac1 and requires further investigation.

The ability of cAMP acting via Epac to exert antifibrotic effects and of profibrotic agents to inhibit Epac expression suggests that strategies to increase Epac expression and activity may have therapeutic potential in preventing or treating tissue fibrosis. However, since Epac regulates numerous effects of cAMP (Gloerich and Bos, 2010; Grandoch *et al.*, 2010; Breckler *et al.*, 2011), it may be difficult to selectively alter Epac expression and actions in fibroblasts. This problem is heightened by the lack of pharmacological inhibitors of Epac and the difficulty in achieving fibroblast-specific targeting of genes (Liu *et al.*, 2010; Österreicher *et al.*, 2011).

Might other approaches be used to increase cAMP and activate Epac in fibroblasts? One possibility is to take advantage of fibroblast-selective expression of signalling components involved in regulating cAMP levels, for example, by activating GPCRs that increase cAMP formation, inhibiting GPCRs that decrease cAMP formation or inhibiting PDEs that hydrolyse cAMP. Results showing that an AC6 adenovirus or fibroblast-targeted AC6 enhances GPCR-promoted cAMP formation and antifibrotic activity (Swaney *et al.*, 2005; Liu *et al.*, 2010) imply that efforts to enhance cAMP levels in fibroblasts may have antifibrotic effects *in vivo*. Preliminary data indicate that fibroblasts selectively express certain GPCRs that regulate cAMP formation (Insel *et al.*, 2012a; the 2009 *BJP Guide to Receptors and Channels*, which is available for free download at <http://www3.interscience.wiley.com/journal/122684220/issue>) and particular isoforms of cAMP-PDE (data not shown) that might be targeted as ways to prevent, blunt or perhaps even reverse fibrosis. Previous data have shown that targeting cAMP-PDEs, in particular PDE4 and PDE1, by family-specific inhibitors and siRNA can inhibit fibroblast activation, EMT and collagen synthesis (Dunkern *et al.*, 2007; Kolosionek *et al.*, 2009; Sachs *et al.*, 2007; Miller *et al.*, 2011). Approaches that increase cAMP levels, such as GPCRs and/or PDE inhibitors in fibroblasts, perhaps combined with Epac or PKA activators, may be novel strategies for the treatment of tissue fibrosis (Leask, 2010; Kisseleva and Brenner, 2011). The GPCR/cAMP/Epac pathway offers intriguing possibilities for new pharmacological approaches directed at achieving antifibrosis *in vivo*.

Acknowledgements

We thank Dr Richard Bunday for initial studies in our laboratory on this topic and Mary Alice Kiisel for assistance in preparation of the manuscript. Work described here was supported by grants from the National Institutes of Health and the Ellison Medical Foundation.

Conflict of interest

None.

References

- Armulik A, Genové G, Betsholtz C (2011). Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. *Dev Cell* 21: 193–215.
- Basoni C, Nobles M, Grimshaw A, Desgranges C, Davies D, Perretti M *et al.* (2005). Inhibitory control of TGF- β 1 on the activation of Rap1, CD11b, and transendothelial migration of leukocytes. *FASEB J* 19: 822–824.
- Bauman KA, Wettlaufer SH, Okunishi K, Vannella KM, Stoolman JS, Huang SK *et al.* (2010). The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. *J Clin Invest* 120: 1950–1960.
- Black SA Jr, Palamakumbura AH, Stan M, Trackman PC (2007). Tissue-specific mechanisms for CCN2/CTGF persistent in fibrotic gingiva: interactions between cAMP and MAPK signaling pathways and prostaglandin E2-EP3 receptor mediated activation of the c-JUN N-terminal kinase. *J Biol Chem* 282: 15416–15429.
- Bos JL (2006). Epac proteins: multi-purpose cAMP targets. *Trends Biochem Sci* 31: 680–686.
- Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C *et al.* (2007). Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. *Science* 317: 807–810.
- Breckler M, Berthouze M, Laurent AC, Crozatier B, Morel E, Lezoualc'h F (2011). Rap-linked cAMP signaling Epac proteins: compartmentation, functioning and disease implications. *Cell Signal* 23: 1257–1266.
- Brown L, Murray F, Zang L, Kipps T, Insel PA (2011). Epac1, an anti-apoptotic protein, is up-regulated in chronic lymphocytic leukemia B cells. *FASEB J* 25: 1090.1.
- Chaffer CL, Weinberg RA (2011). A perspective on cancer cell metastasis. *Science* 331: 1559–1564.
- Chan EC, Dusting GJ, Guo N, Peshavariya HM, Taylor CJ, Dilley R *et al.* (2010). Prostacyclin receptor suppresses cardiac fibrosis: role of CREB phosphorylation. *J Mol Cell Cardiol* 49: 176–185.
- Chen W, Frangogiannis NG (2010). The role of inflammatory and fibrogenic pathways in heart failure associated with aging. *Heart Fail Rev* 5: 415–422.
- Cho ME, Kopp JB (2010). Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. *Expert Opin Investig Drugs* 19: 275–283.
- Clancy RM, Zheng P, O'Mahony M, Izmirly P, Zavadil J, Gardner L *et al.* (2007). Role of hypoxia and cAMP in the transdifferentiation of human fetal cardiac fibroblasts: implications for progression to scarring in autoimmune-associated congenital heart block. *Arthritis Rheum* 56: 4120–4131.
- Cufi S, Vazquez-Martin A, Oliveras-Ferraro C, Martin-Castillo B, Joven J, Menendez JA (2010). Metformin against TGF- β -induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-induced fibrosis. *Cell Cycle* 9: 4461–4468.

- D'Souza KM, Malhotra R, Philip JL, Staron ML, Theccanat T, Jeevanandam V *et al.* (2011). G protein-coupled receptor kinase-2 is a novel regulator of collagen synthesis in adult human cardiac fibroblasts. *J Biol Chem* 286: 15507–15516.
- Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A (2007). Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. *Eur J Pharmacol* 572: 12–22.
- Dussaule JC, Guerrot D, Huby AC, Chadichristos C, Shweke N, Boffa J *et al.* (2011). The role of cell plasticity in progression and reversal of renal fibrosis. *Int J Exp Pathol* 92: 151–157.
- Gloerich M, Bos JL (2010). Epac: defining a new mechanism for cAMP action. *Annu Rev Pharmacol Toxicol* 50: 355–375.
- Grandoch M, Roscioni SS, Schmidt M (2010). The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. *Br J Pharmacol* 159: 265–284.
- Grieb G, Steffens G, Pallua N, Bernhagen J, Bucala R (2011). Circulating fibrocytes-biology and mechanisms in wound healing and scar formation. *Int Rev Cell Mol Biol* 291: 1–19.
- Heusinger-Ribeiro J, Eberlein M, Wahab NA, Goppelt-Struebe M (2001). Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP. *J Am Soc Nephrol* 12: 1853–1861.
- Hinz B (2010). The myofibroblast: paradigm for a mechanically active cell. *J Biomech* 43: 146–155.
- Holz GG, Chepurny OG, Schwede F (2008). Epac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors. *Cell Signal* 20: 10–20.
- Huang SK, Wettlaufer SH, Chung J, Peters-Golden M (2008). Prostaglandin E2 inhibits specific lung fibroblast functions via selective action of PKA and Epac-1. *Am J Respir Cell Mol Biol* 39: 482–489.
- Huang SK, White ES, Wettlaufer SH, Grifka H, Hogaboam CM, Thannickal VJ *et al.* (2009). Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. *FASEB J* 23: 4317–4326.
- Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV *et al.* (2010). Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. *Am J Pathol* 176: 85–97.
- Insel PA, Bourne HR, Coffino P, Tomkins GM (1975). Cyclic AMP-dependent protein kinase: pivotal role in regulation of enzyme induction and growth. *Science* 190: 896–898.
- Insel PA, Snead A, Murray F, Zhang L, Yokouchi H, Katakia T *et al.* (2012a). GPCR expression in tissues and cells: are the optimal receptors being used as drug targets? *Br J Pharmacol* 165: 1613–1616.
- Insel PA, Zhang L, Murray F, Yokouchi H, Zamboni AC (2012b). Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. *Acta Physiol (Oxf)* 204: 277–287.
- Kim A, Son M, Kim KI, Yang Y, Song EY, Lee HG *et al.* (2009). Elevation of intracellular cyclic AMP inhibits NF- κ B-mediated thymosin β 4 expression in melanoma cells. *Exp Cell Res* 315: 3325–3335.
- Kisseleva T, Brenner DA (2011). Anti-fibrogenic strategies and the regression of fibrosis. *Best Pract Res Clin Gastroenterol* 25: 305–317.
- Klijn K, Slivka SR, Bell K, Insel PA (1991). Renal alpha1-adrenergic receptor subtypes: MDCK-D1 cell, but not rat cortical membranes, possess a single population of receptors. *Mol Pharmacol* 39: 407–413.
- Kohyama T, Yamauchi Y, Takizawa H, Itakura S, Kamitani S, Desaki M *et al.* (2009). Procaterol inhibits lung fibroblast migration. *Inflammation* 32: 387–392.
- Kolosonek E, Savai R, Ghofrani HA, Weissmann N, Guenther A, Grimminger F *et al.* (2009). Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. *Mol Biol Cell* 20: 4751–4765.
- Kothapalli D, Hayashi N, Grotendorst GR (1998). Inhibition of TGF-beta-stimulated CTGF gene expression and anchorage-independent growth by cAMP identifies a CTGF-dependent restriction point in the cell cycle. *FASEB J* 12: 1151–1161.
- Krenning G, Zeisberg EM, Kalluri R (2010). The origin of fibroblasts and mechanism of cardiac fibrosis. *J Cell Physiol* 225: 631–637.
- Kriz W, Kaissling B, Le Hir M (2011). Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? *J Clin Invest* 121: 468–474.
- Lakatta EG (2003). Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: cellular and molecular clues to heart and arterial aging. *Circulation* 107: 490–497.
- Leask A (2010). Potential therapeutic targets for cardiac fibrosis: TGF β , angiotensin, endothelin, CCN2 and PDGF, partners in fibroblast activation. *Circ Res* 106: 1675–1680.
- Li Y, Zhu X, Zeng Y, Wang J, Zhang X, Ding YQ *et al.* (2010). FML2 enhances invasion of colorectal carcinoma by inducing epithelial-mesenchymal transition. *Mol Cancer Res* 8: 1579–1590.
- Liu X, Ostrom RS, Insel PA (2004). cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. *Am J Physiol Cell Physiol* 286: C1089–C1099.
- Liu X, Sun SQ, Ostrom RS (2005). Fibrotic lung fibroblasts show blunted inhibition by cAMP due to deficient cAMP response element-binding protein phosphorylation. *J Pharmacol Exp Ther* 315: 678–687.
- Liu X, Sun SQ, Hassid A, Ostrom RS (2006). cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and Smad signaling in cardiac fibroblasts. *Mol Pharmacol* 70: 1992–2003.
- Liu X, Thangavel M, Sun SQ, Kaminsky J, Mahautmr P, Stitham J *et al.* (2008). Adenylyl cyclase type 6 overexpression selectively enhances beta-adrenergic and prostacyclin receptor-mediated inhibition of cardiac fibroblast function because of colocalization in lipid rafts. *Naunyn Schmiedeberg Arch Pharmacol* 377: 359–369.
- Liu X, Li F, Sun SQ, Thangavel M, Kaminsky J, Balazs L *et al.* (2010). Fibroblast-specific expression of AC6 enhances beta-adrenergic and prostacyclin signaling and blunts bleomycin-induced pulmonary fibrosis. *Am J Physiol Lung Cell Mol Physiol* 298: L819–L829.
- MacPherson MR, Molina P, Souchelnytskyi S, Wernstedt C, Martin-Pérez J, Portillo F *et al.* (2010). Phosphorylation of serine 11 and serine 92 as new positive regulators of human Snail1 function: potential involvement of casein kinase-2 and the cAMP-activated kinase protein kinase A. *Mol Biol Cell* 21: 244–253.
- Marian AJ (2009). Experimental therapies in hypertrophic cardiomyopathy. *J Cardiovasc Transl Res* 2: 483–492.

- Maskrey BH, Megson IL, Whitfield PD, Rossi AG (2011). Mechanisms of resolution of inflammation: a focus on cardiovascular diseases. *Arterioscler Thromb Vasc Biol* 31: 1001–1006.
- Masszi A, Kapus A (2011). Smad3 in epithelial-myofibroblast transition. *Cells Tissues Organs* 193: 41–52.
- Masszi A, Speight P, Charbonney E, Ladyga M, Nakano H, Sz?si K *et al.* (2010). Fate-determining mechanisms in epithelial-myofibroblast transition: major inhibitory role for Smad3. *J Cell Biol* 188: 383–399.
- Meier KE, Snively MD, Brown SL, Brown JH, Insel PA (1983). α 1- and β 2-adrenergic receptor expression in the Madin-Darby canine kidney epithelial cell line. *J Cell Biol* 97: 405–415.
- Meran S, Steadman R (2011). Fibroblasts and myofibroblasts in renal fibrosis. *Int J Exp Pathol* 92: 158–167.
- Miller CL, Cai Y, Oikawa M, Thomas T, Dostmann WR, Zaccolo M *et al.* (2011). Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart. *Basic Res Cardiol* 106: 1023–1039.
- Mironov SL, Skorova EY, K?gler S (2011). Epac-mediated cAMP signaling in the mouse model of Rett Syndrome. *Neuropharmacology* 60: 869–877.
- Okunishi K, Sisson TH, Huang SK, Hogaboam CM, Simon RH, Peters-Golden M (2011). Plasmin overcomes resistance to prostaglandin E2 in fibrotic lung fibroblasts by reorganizing protein kinase A signaling. *J Biol Chem* 286: 32231–32243.
- ?sterreichlicher CH, Penz-?sterreichlicher M, Grivennikov SI, Guma M, Koltsova EK, Datz C *et al.* (2011). Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. *Proc Natl Acad Sci U S A* 108: 308–313.
- Parekh A, Sandulache VC, Lieb AS, Dohar JE, Hebda PA (2007). Differential regulation of free-floating collagen gel contraction by human fetal and adult dermal fibroblasts in response to prostaglandin E2 mediated by EP2/cAMP-dependent mechanism. *Wound Repair Regen* 15: 390–398.
- Parekh A, Sandulache VC, Singh T, Cetin S, Sacks MS, Dohar JE *et al.* (2009). Prostaglandin E2 differentially regulates contraction and structural reorganization of anchored collagen gels by human adult and fetal dermal fibroblasts. *Wound Repair Regen* 17: 88–98.
- Park SH, Choi MJ, Song IK, Choi SY, Nam JO, Kim CD *et al.* (2007). Erythropoietin decreases renal fibrosis in mice with uretral obstruction: role of inhibiting TGF- β -induced epithelial-to-mesenchymal transition. *J Am Soc Nephrol* 18: 1497–1507.
- Pinzani M, Macias-Barragan J (2010). Update on the pathophysiology of liver fibrosis. *Expert Rev Gastroenterol Hepatol* 4: 459–472.
- Quaggin SE, Kapus A (2011). Scar wars: mapping the fate of epithelial-mesenchymal-myofibroblast transition. *Kidney Int* 80: 41–50.
- Ramachandran P, Iredale JP (2009). Reversibility of liver fibrosis. *Ann Hepatol* 8: 283–291.
- Sachs BD, Baillie GS, McCall JR, Passino MA, Schachtrup C, Wallace DA *et al.* (2007). P75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. *J Cell Biol* 177: 1119–1132.
- Sandbo N, Kregel S, Taurin S, Bhorade S, Dulin NO (2009). Critical role of serum response factor in pulmonary myofibroblast differentiation induced by TGF- β . *Am J Respir Cell Mol Biol* 41: 332–338.
- Sandulache VC, Parekh A, Li-Korotky HS, Dohar JE (2006). Prostaglandin E2 differentially modulates human fetal and adult dermal fibroblast migration and contraction: implication for wound healing. *Wound Repair Regen* 14: 633–643.
- Sandulache VC, Parekh A, Li-Korotky H, Dohar JE, Hebda PA (2007). Prostaglandin E2 inhibition of keloid fibroblast migration, contraction and transforming growth factor (TGF)- β 1-induced collagen synthesis. *Wound Repair Regen* 15: 122–133.
- Schiller M, Verrecchia F, Mauviel A (2003). Cyclic adenosine 3',5'-monophosphate-elevating agents inhibit transforming growth factor- β -induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism. *Oncogene* 22: 8881–8890.
- Schrimpf C, Duffield JS (2011). Mechanisms of fibrosis: the role of the pericyte. *Curr Opin Nephrol Hypertens* 20: 397–405.
- Selige J, Tenor H, Hatzelmann A, Dunkern T (2010). Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition. *J Cell Physiol* 223: 317–326.
- Serhan CN (2010). Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? *Am J Pathol* 177: 1576–1591.
- Stokman G, Qin Y, Genieser HG, Schwede F, de Heer E, Bos JL *et al.* (2011). Epac-Rap signaling reduces cellular stress and ischemia-induced kidney failure. *J Am Soc Nephrol* 22: 859–872.
- Stumm CL, Wettlaufer SH, Jancar S, Peters-Golden M (2011). Airway remodeling in murine asthma correlates with a defect in PGE2 synthesis by lung fibroblasts. *Am J Physiol Lung Cell Mol Physiol* 301: L636–L644.
- Swaney JS, Roth DM, Olson ER, Naugle JE, Meszaros JG, Insel PA (2005). Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. *Proc Natl Acad Sci U S A* 102: 437–442.
- Togo S, Liu X, Wang X, Sugiura H, Kamio K, Kawasaki S *et al.* (2009). PDE4 inhibitors roflumilast and rolapram augment PGE1 inhibition of TGF β 1-stimulated fibroblasts. *Am J Physiol Lung Cell Mol Physiol* 296: L959–L969.
- Wallace WA, Fitch PM, Simpson AJ, Howie SE (2007). Inflammation-associated remodeling and fibrosis in the lung- a process and an end point. *Int J Exp Pathol* 88: 103–110.
- Windmeier C, Gressner AM (1997). Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. *Gen Pharmacol* 29: 181–196.
- Wynn TA (2011). Integrating mechanisms of pulmonary fibrosis. *J Exp Med* 208: 1339–1350.
- Xing D, Bonanno JA (2009). Effect of cAMP on TGF1-induced corneal keratocyte-myofibroblast transformation. *Invest Ophthalmol Vis Sci* 50: 626–633.
- Yang H, Lee CJ, Zhang L, Sans MD, Simeone DM (2008). Regulation of transforming growth factor β -induced responses by protein kinase A in pancreatic acinar cells. *Am J Physiol Gastrointest Liver Physiol* 295: G170–G178.
- Yates CC, Bodnar R, Wells A (2011). Matrix control of scarring. *Cell Mol Life Sci* 68: 1871–1881.
- Yokoyama U, Patel HH, Lai NC, Aroonsakool N, Roth DM, Insel PA (2008). The cyclic AMP effector Epac integrates pro-and anti-fibrotic signals. *Proc Natl Acad Sci U S A* 105: 6386–6391.

Yu J, Prado GN, Schreiber B, Polgar P, Polgar P, Taylor L (2002). Role of prostaglandin E(2) EP receptors and cAMP in the expression of connective tissue growth factor. *Arch Biochem Biophys* 404: 302–308.

Zhang A, Dong Z, Yang T (2006a). Prostaglandin D2 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in MDCK cells. *Am J Physiol Renal Physiol* 291: F1332–F1342.

Zhang A, Wang MH, Dong Z, Yang T (2006b). Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. *Am J Physiol Renal Physiol* 291: F1323–F1331.

Zhang L, Yun H, Murray F, Lu R, Wang L, Hook V *et al.* (2011). Cytotoxic T lymphocyte antigen-2 alpha induces apoptosis of murine T-lymphoma cells and cardiac fibroblasts and is regulated by cAMP/PKA. *Cell Signal* 23: 1611–1616.